Cargando…
Genomic Surveillance for SARS-CoV-2 — China, September 26, 2022 to January 29, 2023
INTRODUCTION: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has generated 2,431 variants over the course of its global transmission over the past 3 years. To better evaluate the genomic variation of SARS-CoV-2 before and after the optimization of coronavirus disease 2019 (COVID-19...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061763/ https://www.ncbi.nlm.nih.gov/pubmed/37009519 http://dx.doi.org/10.46234/ccdcw2023.026 |
_version_ | 1785017358446755840 |
---|---|
author | Wang, Shiwen Niu, Peihua Su, Qiudong He, Xiaozhou Tang, Jing Wang, Ji Feng, Yenan Chen, Cao Zhao, Xiang Chen, Zhixiao Wang, Wenling Yin, Zeyuan Wu, Yuchao Wu, Changcheng Li, Lili Cui, Aili Zhang, Yan Long, Caiyun Yang, Xiaoyu Zhang, Zhongxian Bo, Hong Xu, Wenbo SARS-CoV-2 Genome Working Group, |
author_facet | Wang, Shiwen Niu, Peihua Su, Qiudong He, Xiaozhou Tang, Jing Wang, Ji Feng, Yenan Chen, Cao Zhao, Xiang Chen, Zhixiao Wang, Wenling Yin, Zeyuan Wu, Yuchao Wu, Changcheng Li, Lili Cui, Aili Zhang, Yan Long, Caiyun Yang, Xiaoyu Zhang, Zhongxian Bo, Hong Xu, Wenbo SARS-CoV-2 Genome Working Group, |
author_sort | Wang, Shiwen |
collection | PubMed |
description | INTRODUCTION: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has generated 2,431 variants over the course of its global transmission over the past 3 years. To better evaluate the genomic variation of SARS-CoV-2 before and after the optimization of coronavirus disease 2019 (COVID-19) prevention and control strategies, we analyzed the genetic evolution branch composition and genomic variation of SARS-CoV-2 in both domestic and imported cases in China (the data from Hong Kong and Macau Special Administrative Regions and Taiwan, China were not included) from September 26, 2022 to January 29, 2023. METHODS: Analysis of the number of genome sequences, sampling time, dynamic changes of evolutionary branches, origin, and clinical typing of SARS-CoV-2 variants submitted by 31 provincial-level administrative divisions (PLADs) and Xinjiang Production and Construction Corps (XPCC) was conducted to assess the accuracy and timeliness of SARS-CoV-2 variant surveillance. RESULTS: From September 26, 2022 to January 29, 2023, 20,013 valid genome sequences of domestic cases were reported in China, with 72 evolutionary branches. Additionally, 1,978 valid genome sequences of imported cases were reported, with 169 evolutionary branches. The prevalence of the Omicron variants of SARS-CoV-2 in both domestic and imported cases was consistent with that of international epidemic variants. CONCLUSIONS: This study provides an overview of the prevalence of Omicron variants of SARS-CoV-2 in China. After optimizing COVID-19 prevention and control strategies, no novel Omicron variants of SARS-CoV-2 with altered biological characteristics or public health significance have been identified since December 1, 2022. |
format | Online Article Text |
id | pubmed-10061763 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-100617632023-03-31 Genomic Surveillance for SARS-CoV-2 — China, September 26, 2022 to January 29, 2023 Wang, Shiwen Niu, Peihua Su, Qiudong He, Xiaozhou Tang, Jing Wang, Ji Feng, Yenan Chen, Cao Zhao, Xiang Chen, Zhixiao Wang, Wenling Yin, Zeyuan Wu, Yuchao Wu, Changcheng Li, Lili Cui, Aili Zhang, Yan Long, Caiyun Yang, Xiaoyu Zhang, Zhongxian Bo, Hong Xu, Wenbo SARS-CoV-2 Genome Working Group, China CDC Wkly Vital Surveillances INTRODUCTION: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has generated 2,431 variants over the course of its global transmission over the past 3 years. To better evaluate the genomic variation of SARS-CoV-2 before and after the optimization of coronavirus disease 2019 (COVID-19) prevention and control strategies, we analyzed the genetic evolution branch composition and genomic variation of SARS-CoV-2 in both domestic and imported cases in China (the data from Hong Kong and Macau Special Administrative Regions and Taiwan, China were not included) from September 26, 2022 to January 29, 2023. METHODS: Analysis of the number of genome sequences, sampling time, dynamic changes of evolutionary branches, origin, and clinical typing of SARS-CoV-2 variants submitted by 31 provincial-level administrative divisions (PLADs) and Xinjiang Production and Construction Corps (XPCC) was conducted to assess the accuracy and timeliness of SARS-CoV-2 variant surveillance. RESULTS: From September 26, 2022 to January 29, 2023, 20,013 valid genome sequences of domestic cases were reported in China, with 72 evolutionary branches. Additionally, 1,978 valid genome sequences of imported cases were reported, with 169 evolutionary branches. The prevalence of the Omicron variants of SARS-CoV-2 in both domestic and imported cases was consistent with that of international epidemic variants. CONCLUSIONS: This study provides an overview of the prevalence of Omicron variants of SARS-CoV-2 in China. After optimizing COVID-19 prevention and control strategies, no novel Omicron variants of SARS-CoV-2 with altered biological characteristics or public health significance have been identified since December 1, 2022. Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2023-02-17 /pmc/articles/PMC10061763/ /pubmed/37009519 http://dx.doi.org/10.46234/ccdcw2023.026 Text en Copyright and License information: Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2023 https://creativecommons.org/licenses/by-nc-sa/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ (https://creativecommons.org/licenses/by-nc-sa/4.0/) |
spellingShingle | Vital Surveillances Wang, Shiwen Niu, Peihua Su, Qiudong He, Xiaozhou Tang, Jing Wang, Ji Feng, Yenan Chen, Cao Zhao, Xiang Chen, Zhixiao Wang, Wenling Yin, Zeyuan Wu, Yuchao Wu, Changcheng Li, Lili Cui, Aili Zhang, Yan Long, Caiyun Yang, Xiaoyu Zhang, Zhongxian Bo, Hong Xu, Wenbo SARS-CoV-2 Genome Working Group, Genomic Surveillance for SARS-CoV-2 — China, September 26, 2022 to January 29, 2023 |
title | Genomic Surveillance for SARS-CoV-2 — China, September 26, 2022 to January 29, 2023 |
title_full | Genomic Surveillance for SARS-CoV-2 — China, September 26, 2022 to January 29, 2023 |
title_fullStr | Genomic Surveillance for SARS-CoV-2 — China, September 26, 2022 to January 29, 2023 |
title_full_unstemmed | Genomic Surveillance for SARS-CoV-2 — China, September 26, 2022 to January 29, 2023 |
title_short | Genomic Surveillance for SARS-CoV-2 — China, September 26, 2022 to January 29, 2023 |
title_sort | genomic surveillance for sars-cov-2 — china, september 26, 2022 to january 29, 2023 |
topic | Vital Surveillances |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061763/ https://www.ncbi.nlm.nih.gov/pubmed/37009519 http://dx.doi.org/10.46234/ccdcw2023.026 |
work_keys_str_mv | AT wangshiwen genomicsurveillanceforsarscov2chinaseptember262022tojanuary292023 AT niupeihua genomicsurveillanceforsarscov2chinaseptember262022tojanuary292023 AT suqiudong genomicsurveillanceforsarscov2chinaseptember262022tojanuary292023 AT hexiaozhou genomicsurveillanceforsarscov2chinaseptember262022tojanuary292023 AT tangjing genomicsurveillanceforsarscov2chinaseptember262022tojanuary292023 AT wangji genomicsurveillanceforsarscov2chinaseptember262022tojanuary292023 AT fengyenan genomicsurveillanceforsarscov2chinaseptember262022tojanuary292023 AT chencao genomicsurveillanceforsarscov2chinaseptember262022tojanuary292023 AT zhaoxiang genomicsurveillanceforsarscov2chinaseptember262022tojanuary292023 AT chenzhixiao genomicsurveillanceforsarscov2chinaseptember262022tojanuary292023 AT wangwenling genomicsurveillanceforsarscov2chinaseptember262022tojanuary292023 AT yinzeyuan genomicsurveillanceforsarscov2chinaseptember262022tojanuary292023 AT wuyuchao genomicsurveillanceforsarscov2chinaseptember262022tojanuary292023 AT wuchangcheng genomicsurveillanceforsarscov2chinaseptember262022tojanuary292023 AT lilili genomicsurveillanceforsarscov2chinaseptember262022tojanuary292023 AT cuiaili genomicsurveillanceforsarscov2chinaseptember262022tojanuary292023 AT zhangyan genomicsurveillanceforsarscov2chinaseptember262022tojanuary292023 AT longcaiyun genomicsurveillanceforsarscov2chinaseptember262022tojanuary292023 AT yangxiaoyu genomicsurveillanceforsarscov2chinaseptember262022tojanuary292023 AT zhangzhongxian genomicsurveillanceforsarscov2chinaseptember262022tojanuary292023 AT bohong genomicsurveillanceforsarscov2chinaseptember262022tojanuary292023 AT xuwenbo genomicsurveillanceforsarscov2chinaseptember262022tojanuary292023 AT sarscov2genomeworkinggroup genomicsurveillanceforsarscov2chinaseptember262022tojanuary292023 |